SCHEMBL49506

SCHEMBL49506

CC(=O)Nc1cccnc1

nearest known ligand 0.65

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.65
NPC1 O15118 4/20 0.65
PKM P14618 1/20 0.65
LMNA P02545 3/20 0.62
HIF1A Q16665 1/20 0.62
ALDH1A1 P00352 2/20 0.61
HTT P42858 2/20 0.61
NAMPT P43490 3/20 0.61
TP53 P04637 1/20 0.59
CYP11B2 P19099 1/20 0.58
KDM4E B2RXH2 3/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
NAPRT Q6XQN6 1/20 0.57
HSD17B10 Q99714 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29602550 1.00 RAB9A (0.65) RAB9ANPC1PKMLMNAHIF1A
Hydrochloric Acid SCHEMBL5095381 0.98 RAB9A (0.62) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL6490312 0.90 GAA (0.55) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL9262080 0.85 RAB9A (0.71) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL30504811 0.83 RAB9A (0.89) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL30051982 0.83 MEN1 (0.77) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL9637653 0.83 MEN1 (0.77) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL11036486 0.82 ALDH1A1 (0.65) RAB9ANPC1PKMLMNAALDH1A1
SCHEMBL12828408 0.82 RAB9A (0.67) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL11213715 0.82 RAB9A (0.72) RAB9ANPC1PKMLMNAHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 474 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119707964-A Preparation method of (8-bromoindolizine-3-yl) (3, 4, 5-trifluoro phenyl) ketone 无锡科华生物科技有限公司 2025-03-28 CN claimed
CN-116478152-A Small molecular marrow cell proliferation inhibitor and preparation method and application thereof 复旦大学 2023-07-25 CN claimed
WO-2023088285-A1 SMALL MOLECULE INHIBITOR AGAINST NASOPHARYNGEAL CARCINOMA, PREPARATION METHOD FOR COMPOUND AND APPLICATION THEREOF 深圳湾实验室 2023-05-25 WO claimed
CN-115210339-A Etching solution for titanium nitride and molybdenum conductive metal wires 弗萨姆材料美国有限责任公司 2022-10-18 CN claimed
CN-107848974-A Aromatic sulfonamide derivatives 拜耳制药股份公司 2018-03-27 CN claimed
CN-107567445-A It can be used as 2 phenyl 3H imidazos [4,5 B] pyridine derivates of mammal EGFR-TK ROR1 activities inhibitor 坎塞拉有限公司 2018-01-09 CN claimed
CN-103958479-B Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof 赛诺菲 2017-06-13 CN claimed
CN-103012397-B Pyrazolo (E)-3-(3-Acetyl-4-hydroxy-5-methoxy-phenyl)-N-(4-hydroxy-1-methyl-3-octyloxy-2-oxo-1,2-dihydro-quinolin-7-yl)-acrylamide, its preparation method and its therapeutic use 赛诺菲 2017-03-01 CN claimed
CN-103687860-A As P2X7Heterocyclic amide derivatives of receptor antagonists ACTELION PHARMACEUTICALS LTD 2014-03-26 CN claimed
US-20130172562-A1 PROCESS FOR THE PREPARATION OF A SINGLE ENANTIOMER OF 3-AMINOPIPERIDINE DIHYDROCHLORIDE DR. REDDY'S LABORATORIES, INC. (US) 2013-07-04 US claimed
US-6436919-B1 LOCAL ANESTHETICS THAT HAVE LONGER DURATION OF ACTION WHILE REDUCING UNDESIRED SIDE EFFECTS THERAVANCE INC. 2002-08-20 US claimed
US-20020107278-A1 Substituted azepino[4,5b]indole derivatives PHARMACIA & UPJOHN COMPANY 2002-08-08 US claimed
WO-2002051983-A2 NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-07-04 WO claimed
EP-1216243-A1 QUINAZOLINONES AND ANALOGUES AND THEIR USE AS LOCAL ANESTHETICS Advanced Medicine, Inc. (US) 2002-06-26 EP claimed
US-20020077318-A1 Substituted azepino[4,5b] indoline derivatives PHARMACIA & UPJOHN COMPANY 2002-06-20 US claimed
WO-2002024701-A2 SUBSTITUTED AZEPINO[4,5B)INDOLE DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 2002-03-28 WO claimed
WO-2002024700-A2 SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 2002-03-28 WO claimed
WO-2001025234-A1 QUINAZOLINONES AND ANALOGUES AND THEIR USE AS LOCAL ANESTHETICS ADVANCED MEDICINE, INC. (US) 2001-04-12 WO claimed
US-5696282-A CATALYTIC REACTION OF A HYDROGEN SULFIDE OR MERCAPTAN WITH UNSATURATED CARBONYL OR CYANO COMPOUND PHILLIPS PETROLEUM COMPANY (US) 1997-12-09 US claimed
US-4124386-A Color diffusion transfer receiving layer comprising polymeric quaternary n-heterocyclic mordant FUJI PHOTO FILM CO., LTD. (JP) 1978-11-07 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107278-A1 Substituted azepino[4,5b]indole derivatives HTR5A, HTR1A, HTR1E RAB9A 698/4885NPC1 1345/4885PKM 3637/4885
US-20130172562-A1 PROCESS FOR THE PREPARATION OF A SINGLE ENANTIOMER OF 3-AMINOPIPERIDINE DIHYDROCHLORIDE RAC3, RAC2, RAPGEF4 RAB9A 45/4885NPC1 3781/4885PKM 2882/4885
US-20020077318-A1 Substituted azepino[4,5b] indoline derivatives HTR5A, HTR1A, HTR4 RAB9A 751/4885NPC1 1176/4885PKM 3291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.